Research Article
Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway
Table 1
Association between Rab22a expression and clinical parameters in 101 patients with thyroid disease.
| Clinicopathological characteristics | Rab22a positive | Rab22a negative | Total | |
| Age (Y) | | | | | ≤55 | 42 | 11 | 53 | 0.280 | >55 | 12 | 6 | 18 | | Gender | | | | | Male | 15 | 6 | 21 | 0.554 | Female | 39 | 11 | 50 | | Tumor size | | | | | ≤2 cm | 35 | 13 | 48 | 0.553 | >2 cm | 19 | 4 | 23 | | Lymphatic metastasis | | | | | Negative | 23 | 8 | 31 | 0.746 | Positive | 31 | 9 | 40 | | TNM stage | | | | | I | 45 | 14 | 59 | 0.925 | II-IV | 9 | 3 | 12 | | BRAF | | | | | Wild-type | 27 | 8 | 35 | 0.854 | V600E | 19 | 5 | 24 | | Histological type | | | | | Papillary thyroid carcinoma | 24 | 7 | 31 | <0.001 | Follicular carcinoma | 24 | 9 | 33 | <0.001 | Thyroid medullary carcinoma | 6 | 1 | 7 | <0.001 | Nodular goiter | 0 | 30 | 30 | |
|
|
P <0.05 (Fisher’s test).
|